TL-532, a novel rationally designed TLR3 agonist, induces tumor-specific apoptosis, immune simulation, life-long anti-tumor auto-vaccination, and reverses resistance to immune checkpoint inhibitors
OTS – October 2022, Phoenix (USA) – M Bonnin
Tollys presents new data at OTS 2022, demonstrating anti-tumor activity of TL-532
Results highlight specificity of TLR3-agonist TL-532, that induces lifelong anti-tumor auto-vaccination and reverses resistance to immune checkpoint inhibitors
TL-532 specific TLR3 agonist induces lifelong anti-tumor autovaccination, cross-immunity against unrelated cancer and reverses resistance to immune checkpoint inhibitors
IRCI 15-17 June 2022 Lyon – M Bonnin
TL-532 specific TLR3 agonist induces lifelong anti-tumor autovaccination, cross-immunity against unrelated cancer and reverses resistance to immune checkpoint inhibitors
AACR 8-13 Avril 2022 New Orleans – S Thierry
TOLLYS : la phase clinique bientôt en vue (La Gazette du Laboratoire – Juillet 2022)
Un produit très prometteur et une phase clinique prévue en 2024
Recent Comments